key: cord-0856472-0uk5iw4h authors: Salehi, Mohammadreza; Hosseini, Hamed; Jamshidi, Hamid Reza; Jalili, Hasan; Tabarsi, Payam; Mohraz, Minoo; Karimi, Hesam; Lotfinia, Majid; Aalizadeh, Reza; Mohammadi, Mehrdad; Ramazi, Shahin; Abdoli, Asghar title: Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern date: 2022-03-03 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2022.02.030 sha: 7d10a4a2aa21b1283ae1d45e988ffbabfc8ba57e doc_id: 856472 cord_uid: 0uk5iw4h Objectives BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against the variants of concern (VOCs). We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain. Methods The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test (cVNT). Correlation of spike (S) protein antibody and anti-receptor binding domain (RBD) with neutralizing activity was investigated. Results Results of the current study demonstrated 29/32 (90.6%; 95%CI: 75.0-98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28/32 (87.50 %, 87.50 %) and 24/32 (75 %) of the recipients were able to produce NAbs versus Alpha, Beta and Delta variants, respectively. Serum virus-neutralizing titers for different SARS-CoV-2 strains were weakly correlated with anti-RBD antibodies (Spearman r = 36-42, p values < 0.05), but not S-binding antibodies (p values > 0.05). Conclusions Although there was a reduction in neutralization titers against the variants of Alpha, Beta and Delta than Wuhan strain, the BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate with the 51 lapse of time, leading to variants of concern (VOCs) in the circulating viral strains during the 52 ongoing COVID-19 pandemic (1, 2) . The emergence of VOCs posed an increased risk to affect 53 global epidemiology due to their high transmissibility, becoming the most dominant strain in the 54 affected countries. The VOCs can lead to waves of infection and potentially escape vaccine-55 induced immune responses due to their ability in immune evasion. 56 The most important emerging VOCs that were isolated from different parts of the world are Alpha is characterized by 37 amino acid substitutions in the S protein, 15 of these occurring in the 62 receptor binding domain which made omicron to evade neutralizing antibody stimulated via past 63 infection or vaccination (5, 6). Omicron replicated rapidly than all other SARS-CoV-2 in the upper 64 respiratory system but displayed less efficient replication and fusion activity at lower respiratory 65 system (7). Also, it is indistinct whether its high rate of transmissibility is due to intrinsic 66 virological characteristic or immune evasion (8). 67 If the pandemic of SARS-CoV-2 is not effectively controlled, the emerging VOCs of the virus, 68 which diverge sharply from their ancestral strain counterparts, can challenge global health system 69 (9). Due to the emergence of antigenic distance variants, resistance to neutralizing antibodies 70 (NAbs) provoked by vaccination is the main concern (10). Current evidence shows that the 71 J o u r n a l P r e -p r o o f protection level provided by each variant of SARS-CoV-2 mutation may be different (11). In 72 COVID-19, an indispensable component of acquired immunity against this virus is the induction 73 of NABs that attach to the SARS-CoV-2 spike (S) protein and block the virus attachment to cell 74 receptors (12). NAbs mostly inhibit the binding of the virus ligand to cellular receptors; though, in 75 some cases, they may block conformational changes essential for fusion of the virus with the host 76 cell membrane or proteolytic cleavage (13). NAbs evaluations are valuable to determine vaccine 77 potency against VOCs and to predict vaccine breakthrough infections (14). The BIV1-CovIran vaccine as an inactivated vaccine (manufactured by Shifa Pharmed Industrial 79 Group) induced high levels of NAbs against Wuhan strain of SARS-CoV-2 in preclinical studies 80 and phase I, II and III clinical trials (15). However, it remains unclear whether formulated SARS- CoV-2-inactivated vaccines developed against the original Wuhan strain of the virus will still be 82 effective against VOCs. To clarify this, we examined and reported the neutralizing activity of sera 83 from BIV1-CovIran vaccinees against the newly emerged variants of SARS-CoV-2. In this study, we assessed the effect of the original strain of Wuhan SARS-CoV-2, and VOCs such 86 as Alpha, Beta and Delta on humoral immunity elicited by inactivated vaccination. To this end, 87 we studied one cohort of individuals vaccinated with two doses of the CovIran vaccine. A cVNT was conducted to verify the presence of neutralizing antibodies in sera. The sera from 114 vaccinees were assessed against SARS-CoV-2 variants as described earlier (16). Briefly, sera 115 J o u r n a l P r e -p r o o f samples were incubated at 56 C 0 for 30 minutes to inhibit the complement activity. Next, each 116 serum sample was diluted two-fold, serially. Each dilution was exposed with an equal amount of 117 100 TCID50 of SARS-CoV-2 2.After 90 minutes incubating at 37°C with 5% CO, the mixture and Beta variants at detectable levels (Fig.1a) . Beta and Delta variants were reduced 2-and 5.6-fold relative to Wuhan strain (p < 0.0018 and p < 154 0.0001, respectively) while neutralizing activity against Alpha variant was not considerably 155 changed in sera (Fig.1c) . In serum samples from participants who had received a second dose of 156 CovIran 28 days earlier or 42 days earlier, we found no significant difference in neutralizing 157 activity. This indicated that there is no change in neutralizing capacity against SARS-CoV-2 at 158 fourth week to sixth week after vaccination (Fig.1d) . In The reduction in neutralizing capacity against SARS-CoV-2 Wuhan strain was greater for older 160 than younger adults, whereas no correlation was found between age and GMTs for VOCs after 161 J o u r n a l P r e -p r o o f vaccination (Fig.1e, f) . Wuhan strain GMT for older persons with age > 50 was reduced 2.4-fold 162 relative to that with age < 50 (p < 0.0167). 163 We found that Wuhan strain neutralizing titers were highly correlated with Alpha variant at the 164 individual level (Fig.1g) . In contrast, the correlation of the neutralizing titers for Wuhan strain was 165 weak with Beta (Fig.1h) , and Delta variants (Fig.1i) . Subsequently, RBD-and S-binding antibody levels in vaccinees were measured through ELISA. Compared to that of the placebo cohort, antibody concentrations of vaccinated individual sera were 169 2.7-fold higher (p < 0.0001) for RBD (Fig.2a ) and 3.9-fold higher (p < 0.0001) for S 170 (Fig.2b) . Moreover, we assessed RBD-and S-binding antibody concentrations on day 0 (pre-171 dose), day 28 and day 42 (4 and 6 weeks after the second dose, respectively). Totally, there was a 172 considerable increase in RBD-and S-binding antibody levels 28 and 42 days following the second 173 vaccinations (Fig.2c,d) . Additionally, post-vaccination S-binding antibody levels at day 42 were 174 notably higher than the antibody levels induced by the vaccine at day 28 (p < 0.0001) (Fig.2d ). However, there was no further remarkable change in RBD-binding antibody levels between day 176 28, and 42 (p = 0.1010) (Fig.2c) . neutralization titers was observed in this study (Fig.3a) . Moreover, anti-RBD antibodies positively 180 correlated with neutralization titers in each strain in our study (Fig.3b-e) . This indicated that the 181 concentration of variant-specific RBD-binding antibody is commensurate with live virus 182 neutralization activity against each strain. It is important to note that high antibody levels could 183 also be observed in the absence of neutralization in some participants. However, no significant 184 J o u r n a l P r e -p r o o f correlation was observed between the levels of anti-S antibody and virus neutralization titers for 185 all strains (Fig.3f) . In this study, humoral response cross-reactivity to the original SARS-CoV-2 and also new 188 emerging variants was evaluated in sera collected from BIV1-CovIran vaccinees. We report that Ramona and colleges reported that, high and low anti-S1 IgG levels were correlated with a positive 219 predictive rate of 72.0% for high-titer NAbs and a negative predictive rate of 90.8% for low-levels neutralizing titers (IC50 < 4), and seroconservative titers (IC50 > 4) against the indicated wildtype Wuhan 323 strain and VOCs. Individuals with an IC50 of neutralization above 4 were considered as neutralizers and are 324 showed in teal. Non-neutralizers are in grey. c) IC50 titers of sera from vaccinated individuals (n = 32) 325 against Wuhan strain, Alpha, Beta and Delta variants. Each dot represents the IC50 for a single donor. The 326 black lines showed geometric mean titers (GMTs). The threshold for neutralizing activity was set at an IC50 327 of 16 (dashed line). A two-sided Friedman test with Dunn's multiple comparison was conducted between 328 each of the SARS-CoV-2 strains. d) Neutralizing titer of sera from vaccinees, sampled at week 4 329 vaccination (n = 13) and week 6 after vaccination (n = 19) with CovIran. A multiple Mann-Withey test was Endemic SARS-CoV-2 253 polymorphisms can cause a higher diagnostic target failure rate than estimated by aggregate global 254 sequencing data SARS-CoV-2 Variants. SARS-CoV-2 Spike Protein Convergent Evolution Variants: Differences and Potential of Immune Evasion. Frontiers in Cellular and Infection Microbiology Characterization of the 263 novel SARS-CoV-2 Omicron (B. 1.1. 529) Variant of Concern and its global perspective Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell 267 entry mechanism SARS-CoV-2 Omicron variant shows less 269 efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells: 270 Omicron variant replication kinetics SARS-CoV-2 Omicron variant 272 replication in human bronchus and lung ex vivo The emergence of SARS-CoV-2 variants threatens to decrease the 274 efficacy of neutralizing antibodies and vaccines The challenge of emerging SARS-CoV-2 mutants to vaccine development Covid-19: Moderna plans booster doses to counter variants SARS-CoV-2 structural features may 282 explain limited neutralizing-antibody responses. npj Vaccines Vaccine breakthrough 284 infections with SARS-CoV-2 variants Safety and potency 286 of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study COVID-19 vaccines: Keeping pace with SARS-289 CoV-2 variants Susceptibility of circulating 291 SARS-CoV-2 variants to neutralization Neutralising antibody activity 293 against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. The Lancet Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in 297 Sri Lanka. medRxiv Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A 300 Prospective Study in 283 Health Workers Antibody 302 persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19 Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. 306 bioRxiv Formalin-312 treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type 313 immune responses. Japanese journal of infectious diseases Correlation of vaccine age with serum neutralizing antibody titer against Wuhan strain and the VOCs Analysis for comparison of neutralizing activity of age groups was 334 performed by a Mann-Whitney test. g-i) Correlation of neutralizing capacity against Alpha (g) and Delta (i) variants with that of wildtype Wuhan strain. Spearman r was used to determine correlations Values from statistical analysis are depicted in gray box Levels of RBD-and S-binding antibodies in vaccinees. a) Comparison of anti-RBD antibodies 338 titers in the vaccinees after 2nd dose of CovIran vaccine (intervention, n = 36) and nonvaccinated persons 339 (placebo, n = 12). b) Comparison of S-binding antibodies levels in the total vaccinees (intervention) and 340 nonvaccinated persons (placebo). A Mann-Whitney test was implemented for comparisons RBD-binding antibody levels from 4 weeks (Day 28) to 6 weeks (Day 42) after COVID-19 vaccination Post-vaccination changes in S-binding antibody levels. Statistical analysis was carried out via a paired nonparametric Wilcoxon test Figure 3. Correlation of serological parameters with serum IC50 titers against Wuhan strain and VOCs 345 Beta and Delta. a-e) Nonparametric Spearman correlation of RBD-binding antibody levels with 346 IC50 titers from neutralizing sera collected from vaccine recipients (n = 32) against the SARS-CoV-2 (a) Beta (d) and Delta (e). Spearman r and p values are indicated in the rectangular 348 box in each graph. f) Correlation of S-binding antibody levels with IC50 titers from neutralizing sera 349